Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Get Free Report) has received a consensus rating of "Moderate Buy" from the six ratings firms that are covering the stock, MarketBeat Ratings reports. One...